A Quantitative Cross-Sectional Study Assessing the Prevalence and Distribution of Renal Amyloidosis Subtypes (AA and non-AA) in Biopsy-Proven Adult Cases: Renal Amyloidosis Subtypes (AA and non-AA) in Biopsy-Proven Adult Cases

Maidah Noor; Mudassar Hussain; Usman Hassan; Maryam Hameed

doi:10.54393/pjhs.v7i5.3778

Authors

Maidah Noor Department of Pathology, Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan
Mudassar Hussain Department of Pathology, Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan
Usman Hassan Department of Pathology, Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan
Maryam Hameed Department of Pathology, Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v7i5.3778

Keywords:

Amyloidosis, Renal Amyloidosis, AA Amyloidosis, Non-AA Amyloidosis, Prevalence, Biopsy-Proven Kidney Disease

Abstract

Renal amyloidosis is a multisystem disease characterized by the deposition of misfolded proteins in various organs, leading to organ dysfunction. Renal amyloidosis subtypes vary across populations, depending on underlying conditions such as inflammatory diseases and plasma cell disorders. Objectives: To evaluate the prevalence and distribution of the different subtypes of renal amyloidosis. Methods: The sample for this quantitative, observational, cross-sectional study comprised 94 patients with biopsy-proven renal amyloidosis, aged 18 years or older, diagnosed during the period between January and December 2025. Renal biopsies were analyzed with the help of Congo red stain to confirm the amyloid deposition, and subtyping was done with the help of amyloid A (AA) immunostain. Cases with negative AA staining were classified as non-AA amyloidosis. Results: The most common subtype was AA amyloidosis (80%), followed by non-AA amyloidosis (20%). Males were 54.3 percent of the participants, while females were 45.7%. Mean age was 51.19 ± 20.45 years. There were no statistically significant gender differences in the distribution of amyloid subtypes or in biochemical parameters (p>0.05). Conclusions: The most common type of renal amyloidosis was AA amyloidosis, in which there were no significant gender-based differences in demographic or biochemical factors. The results are valuable to aid clinical planning and disease management.

References

Feitosa VA, Neves PD, Jorge LB, Noronha IL, Onuchic LF. Renal Amyloidosis: A New Time for A Complete Diagnosis. Brazilian Journal of Medical and Biological Research. 2022; 55: e12284. doi: 10.1590/1414-431x2022e12284.

Goldis R, Kaplan B, Kukuy O, Arad M, Magen H, Shavit-Stein E et al. Diagnostic Challenges and Solutions in Systemic Amyloidosis. International Journal of Molecular Sciences. 2023 Feb; 24(5): 4655. doi: 10.3390/ijms24054655.

Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL Amyloidosis: A Real-World Study Using US Claims Data. Blood Advances. 2018 May; 2(10): 1046-53. doi: 10.1182/bloodadvances.2018016402.

Ríos-Tamayo R. Epidemiology of Systemic Light-Chain (AL) Amyloidosis. Lymphatics. 2025 Aug; 3(3): 25. doi: 10.3390/lymphatics3030025

Adams M. Epidemiology and the Leading Causes of Death. InEpidemiology for Athletic Trainers. 2024 Jun: 3-19. doi: 10.4324/9781003523994-2.

Bharati J, Lahoud OB, Jhaveri KD, Izzedine H. AA Amyloidosis Associated With Cancers. Nephrology Dialysis Transplantation. 2023 Jun; 38(6): 1366-74. doi: 10.1093/ndt/gfac217.

Vasstrand HJ, Raki M, Skrunes R, Leh S, Thomsen J, Gudmundsdottir H et al. Epidemiology and Clinical Presentation of Kidney Amyloidosis Have Changed Over the Past Three Decades: A Nationwide Population-Based Study. BioMed Central Nephrology. 2025 Jun; 26(1): 272. doi: 10.1186/s12882-025-04136-w.

Jogpal V, Sanduja M, Dutt R, Garg V, Tinku. Advancement of Nanomedicines in Chronic Inflammatory Disorders. Inflammopharmacology. 2022 Apr; 30(2): 355-68. doi: 10.1007/s10787-022-00927-x.

De la Cruz Jasso MA, Mejía-Vilet JM, del Toro-Cisneros N, Aguilar-León DE, Morales-Buenrostro LE, Herrera G et al. Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Distribution in a Mexican Population: An Autopsy Study. American Journal of Clinical Pathology. 2023 Jan; 159(1): 89-97. doi: 10.1093/ajcp/aqac138.

Smorti M, Ponti L, Soffio F, Argirò A, Perfetto F, Zampieri M et al. Prevalence of Anxiety and Depression Symptoms in A Sample of Outpatients with ATTR Cardiac Amyloidosis. Frontiers In Psychology. 2023 Jan; 13: 1066224. doi: 10.3389/fpsyg.2022.1066224.

Emami Kazemabad MJ, Asgari Toni S, Tizro N, Dadkhah PA, Amani H, Akhavan Rezayat S et al. Pharmacotherapeutic Potential of Pomegranate in Age-Related Neurological Disorders. Frontiers in Aging Neuroscience. 2022 Sep; 14: 955735. doi: 10.3389/fnagi.2022.955735.

Staron A, Zheng L, Doros G, Connors LH, Mendelson LM, Joshi T et al. Marked Progress in AL Amyloidosis Survival: A 40-Year Longitudinal Natural History Study. Blood Cancer Journal. 2021 Aug; 11(8): 139. doi: 10.1038/s41408-021-00529-w.

Fedotov SA, Khrabrova MS, Anpilova AO, Dobronravov VA, Rubel AA. Noninvasive Diagnostics of Renal Amyloidosis: Current State and Perspectives. International Journal of Molecular Sciences. 2022 Oct; 23(20): 12662. doi: 10.3390/ijms232012662.

Mirioglu S, Uludag O, Hurdogan O, Kumru G, Berke I, Doumas SA et al. AA Amyloidosis: A Contemporary View. Current Rheumatology Reports. 2024 Jul; 26(7): 248-59. doi: 10.1007/s11926-024-01147-8.

Mirgh S, Yanamandra U, Vishvanathan GK, Gundeti S, Khattry N, John MJ et al. Clinical Perspectives on Amyloidosis in India: A Systematic Literature Review. Clinical Lymphoma, Myeloma and Leukemia. 2025 Sep; 25(9): e675-84. doi: 10.1016/j.clml.2025.05.014.

Mosli M, Alawadhi S, Hasan F, Abou Rached A, Sanai F, Danese S. Incidence, Prevalence, and Clinical Epidemiology of Inflammatory Bowel Disease in the Arab World: A Systematic Review and Meta-Analysis. Inflammatory Intestinal Diseases. 2021 Sep; 6(3): 123-31. doi: 10.1159/000518003.

Muchtar E, Dispenzieri A, Magen H, Grogan M, Mauermann M, McPhail ED et al. Systemic Amyloidosis from A (AA) to T (ATTR): A Review. Journal of Internal Medicine. 2021 Mar; 289(3): 268-92. doi: 10.1111/joim.13169.

Zaroui A, Lafont C, Kharoubi M, Audureau E, Bézard M, Hentati M et al. Men and Women Differ About the Prevalence, Phenotype, and Prognosis of Wild-Type Transthyretin Amyloid Cardiomyopathy. Amyloid. 2025 Jul; 32(3): 255-66. doi: 10.1080/13506129.2025.2507921.

Kumar N, Zhang NJ, Cherepanov D, Romanus D, Hughes M, Faller DV. Global Epidemiology of Amyloid Light-Chain Amyloidosis. Orphanet Journal of Rare Diseases. 2022 Jul; 17(1): 278. doi: 10.1186/s13023-022-02414-6.

Mansour N, Khalleefah M, Soliman N, Shaglabow S, Abdulgadir S, Ramdan A. Association of Gender, Age, Physiological, and Biochemical Parameters among Chronic Renal Failure Patients at Zawia Kidney Hospital. Khalij-Libya Journal of Dental and Medical Research. 2023 Dec: 171-7. doi: 10.47705/kjdmr.237215.